Welcome to BioVacSafe Project
BioVacSafe – Biomarkers for enhanced vaccines immunosafety – is a 5 years project funded by Innovative Medicine initiative (IMI).
The goal of BioVacSafe is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. By bringing together for the first time three of Europe’s leading vaccine development and manufacture companies as well as top experts from academic institutions and small and medium-sized enterprises (SMEs), the project will ultimately accelerate the development and introduction of a new generation of safer, more effective vaccines. By sharing their expertise, the BioVacSafe partners have a unique opportunity to make progress in this important area.
Project Description
On March 1st 2012 the IMI-JU funded project – Biomarkers for Enhanced Vaccine Safety (BioVacSafe) – initiated its collaborative work to develop new tools that will improve the evaluation and monitoring of vaccine immunosafety.
BioVacSafe is a public private consortium of 19 partners involving three of Europe’s leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO) actors.
The total budget of the project is 30.2 millions of Euros and it will last for five years.
Project Objectives
The overall objective of the project is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market.
The three specific objectives of the project are:
- the characterization of early inflammation induced by vaccines currently on the market and the identification and validation of biomarkers of early inflammation and allergic responses;
- the identification and validation of early biomarkers of autoimmunity and their use to help identifying population at risk of developing autoimmunity;
- the analysis of the incidence and epidemiology of autoimmune disease in the general population and the link to genetic background or previous events in the life of patients, including severe effects, such as anaphylactic shock.